Ardelyx, Inc., a biotechnological drug manufacturing company based in Fremont, United States, continues to focus on developing pharmaceuticals aimed at correcting mineral metabolism imbalances and metabolic disorders. The company’s approach involves targeting specific transporters, channels, and receptors located on the epithelia of the gastrointestinal tract. By modulating these functions, Ardelyx’s products are designed to address health issues related to these imbalances and disorders, serving patients within the United States.
As of April 1, 2026, Ardelyx’s stock closed at $5.94 on the Nasdaq exchange, where it is publicly traded. The company’s market capitalization stands at approximately $1.46 billion USD. Over the past year, Ardelyx’s stock has experienced significant volatility, reaching a 52-week high of $8.40 on January 22, 2026, and a low of $3.21 on May 14, 2025. The company’s price-to-earnings ratio is currently -23.06, reflecting its financial performance and market expectations.
In recent regulatory filings, Ardelyx disclosed that its Chief Medical Officer, Dinavahi Rajani, holds restricted stock units that vest over time and a stock-option award maturing in 2036. Additionally, a power-of-attorney document was filed, appointing company executives to execute required regulatory filings on Rajani’s behalf. These updates provide insight into insider holdings and compliance arrangements for the company’s securities, without indicating any other material corporate actions or financial results.
Ardelyx, Inc. made its initial public offering in June 2014 and continues to operate within the health care sector, specifically within the biotechnology industry. For more information about their offerings and initiatives, interested parties can visit their website at www.ardelyx.com .
